Cibus, Inc. (CBUS) — SEC Filings
Cibus, Inc. (CBUS) — 38 SEC filings. Latest: 8-K (Mar 27, 2026). Includes 26 8-K, 5 10-Q, 2 DEF 14A.
Overview
Cibus, Inc. (CBUS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 27, 2026: Cibus, Inc. filed an 8-K on March 27, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The filing includes various documents such as an iXBRL 8-K, exhibits, and XBRL data. The company's mailing and business address is 6455 Nancy Ridge Drive, San Diego
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Cibus, Inc. is neutral.
Filing Type Overview
Cibus, Inc. (CBUS) has filed 26 8-K, 1 424B5, 5 10-Q, 2 DEF 14A, 1 8-K/A, 2 10-K, 1 SC 13G/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of CBUS's 34 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $615K |
| Net Income | -$24.303M |
| EPS | -$0.46 |
| Debt-to-Equity | 5.73 |
| Cash Position | $23.886M |
| Operating Margin | -396.1% |
| Total Assets | $330.226M |
| Total Debt | $278.197M |
Key Executives
- Rory Riggs
- Michael Carr
- Dr. Jeffrey R. Binder
- Dr. Alan R. Kahn
- Dr. Christian Albrechtsen
- Dr. J. Marc Sheridan
- Dr. Jeffrey L. Fox
- Mr. David E. S. Stein
- Abigail P. Johnson
Industry Context
Cibus, Inc. operates in the biotechnology or agricultural technology sector, focusing on developing innovative solutions. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial capital investment and strategic partnerships to bring products to market. The competitive landscape is dynamic, with both established players and emerging startups vying for market share and technological advancements.
Top Tags
corporate-governance (10) · 8-K (7) · financials (4) · management-change (3) · material-agreement (3) · 10-Q (3) · executive-compensation (3) · corporate-event (3) · regulatory-filing (3) · Cibus (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK Number | 0001705843 | Identifies Cibus, Inc. in SEC filings. |
| Filing Date | 2026-03-27 | Date the 8-K was accepted by the SEC. |
| 424B5 Document Size | 368286 | Indicates the size of the main prospectus document in bytes. |
| Complete Submission Text File Size | 641201 | Size of the full submission text file in bytes. |
| Net Loss (Q3 2025) | $24.303M | Significant improvement from $201.459M loss in Q3 2024, largely due to reduced goodwill impairment. |
| Revenue (Q3 2025) | $615K | Decreased from $1.667M in Q3 2024, indicating ongoing challenges in revenue generation. |
| R&D Expenses (Q3 2025) | $10.784M | Reduced from $12.990M in Q3 2024, reflecting cost-cutting measures. |
| SG&A Expenses (Q3 2025) | $5.269M | Decreased from $7.682M in Q3 2024, contributing to the narrowed net loss. |
| Cash and Cash Equivalents (Sep 30, 2025) | $23.886M | Increased from $14.433M at Dec 31, 2024, suggesting recent capital infusion. |
| Accumulated Deficit (Sep 30, 2025) | $826.965M | Expanded from $731.166M at Dec 31, 2024, highlighting continued operational losses. |
| Royalty Liability - Related Parties (Sep 30, 2025) | $225.517M | Increased from $199.442M at Dec 31, 2024, a significant and growing liability. |
| Weighted Average Class A Shares Outstanding (Q3 2025) | 52,925,776 | Increased from 23,586,746 in Q3 2024, indicating significant share dilution. |
| Net Loss | $75.950M | Increased from $55.450M year-over-year for the six months ended June 30, 2025, primarily due to goodwill impairment. |
| Goodwill Impairment | $20.950M | Recognized for the six months ended June 30, 2025, significantly impacting net loss. |
| Cash and Cash Equivalents | $36.463M | Increased from $14.433M at December 31, 2024, largely due to a registered offering. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant stake in Cibus, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Cibus, Inc. (CBUS)?
Cibus, Inc. has 38 recent SEC filings from Jan 2024 to Mar 2026, including 26 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CBUS filings?
Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cibus, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cibus, Inc. (CBUS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cibus, Inc.?
Key financial highlights from Cibus, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CBUS?
The investment thesis for CBUS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cibus, Inc.?
Key executives identified across Cibus, Inc.'s filings include Rory Riggs, Michael Carr, Dr. Jeffrey R. Binder, Dr. Alan R. Kahn, Dr. Christian Albrechtsen and 4 others.
What are the main risk factors for Cibus, Inc. stock?
Of CBUS's 34 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Cibus, Inc.?
Recent forward-looking statements from Cibus, Inc. include guidance on {"claim":"FMR LLC will maintain a significant stake in Cibus, Inc. for the foreseeable future.","entity":"FMR LLC","targ.